Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10950730 | 0.91 | HTT (0.61) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| Cadaverine Tartrate SCHEMBL30467086 | 0.91 | LMNA (0.60) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL2741815 | 0.90 | HTT (0.72) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL10490888 | 0.89 | LMNA (0.57) | LMNASMN1; SMN2HTTTGM2CTRB1 | |
| SCHEMBL13055383 | 0.89 | LMNA (0.80) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL28904365 | 0.86 | LMNA (0.65) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL18254066 | 0.86 | HTT (0.81) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| Benzyl Phenethylcarbamate SCHEMBL4287199 | 0.84 | LMNA (0.73) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL375858 | 0.84 | LMNA (0.73) | LMNASMN1; SMN2HTTTGM2L3MBTL1 | |
| SCHEMBL9874334 | 0.84 | HTT (0.79) | LMNASMN1; SMN2HTTTGM2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696500-B2 | BIOACTIVE SUBSTANCE HAVING ACIDIC GROUP AND A BIODEGRADABLE POLYMER HAVING AN OPTIONALLY PROTECTED BASIC GROUP, SUCH AS A POLYLACTONE THAT HAS BEEN ESTERIFIED, AMIDATED, OR THIOESTERIFIED WITH A COMPOUND HAVING CYCLIC AMINO GROUPS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| EP-0815853-B1 | Sustained-release preparation for bioactive substance having an acidic group | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20010038854-A1 | Sustained-release preparation | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6264970-B1 | BIODEGRADABLE POLYMER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-0815853-A2 | Sustained-release preparation for bioactive substance having an acidic group | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0074599-A1 | 5,6-cis-Carbapenem derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-03-23 | — | — | EP | disclosed |
| EP-0032400-A1 | (3SR, 4RS)-3-((RS)-1-hydroxyethyl)- and -((RS)-1-acyloxyethyl)-2-oxo-4-azetidineacetic acid compounds and a process for preparing the same | MERCK & CO. INC. (US) | 1981-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010038854-A1 | Sustained-release preparation | BMP2, PGF, AREG | LMNA 1563/4885SMN1; SMN2 1666/4885HTT 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.